SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabien Tech. Regulatory News (SNT)

Share Price Information for Sabien Tech. (SNT)

Share Price is delayed by 15 minutes
Get Live Data
3.75    0.00 (0.00%)
Bid:
3.50
Ask:
4.00
Spread: 0.50 (14.286%)
Market Cap: £1.04m
SNT Live PriceLast checked at - London Stock Exchange

Intraday Sabien Tech. Share Chart

Trading Update

7 Jul 2021 07:00

RNS Number : 3698E
Sabien Technology Group PLC
07 July 2021
 

7 July 2021

 

Sabien Technology Group plc

("Sabien" or "the Company" or "the Group")

Trading Update

Sabien Technology Group plc (AIM:SNT), a company focused on building a portfolio of solutions in the heating, cooling, and transportation sectors, announces today a trading update ahead of the publication of its final results for the year ended 30 June 2021.

This trading update is published against a socio-economic background whose trends continue to support Sabien's strategic direction. As Governments in the US and Europe look to the post-COVID landscape, it is clear that changes in working locations, living conditions and transportation are all being actively accommodated. Extending its operations in and knowledge of the wider industrial heating markets, Sabien is actively pursuing targets within the non-refrigerant based cooling, battery recycling and reproduction, and waste to energy sectors together with a number of other "green energy" environmental opportunities in a variety of markets.

Sabien has raised £1.7m (gross) during the year to 30 June 2021. Through this financing, the Executive Chairman, Richard Parris, has further increased his position as a significant (10.3%) shareholder in the Company. Consistent with the strengthening of the Company's financial position, Sabien's issued shares were consolidated to provide a more representative basis for the Company's improved prospects. During this period, the Company exited the Reverse Take-Over (RTO) discussions with Ptarmigan Health Destinations and trading in its shares resumed on AIM.

In the first half of the 2021 financial year in comparison to the same period in the prior year, Sabien reported a near threefold increase in revenue and gross profit, substantially reducing the interim loss before tax and improving operational cash generation.

Strategically, the Company made an investment into Aeristech, a leading manufacturer of components for hydrogen fuel cells, secured a £400k contract with a UK Government department for the use of M2G technology, and formed a US subsidiary from which it will source US acquisition opportunities in addition to expanding the US market for Sabien's European products and services.

Since the publication of its interim results on 25 March 2021, the Company has made further considerable progress within its strategic development.

Operationally, Sabien has extended the application of its M2G technology with its Cloud-based subscription service now available across more than five sites within public sector, sports, and pharmaceutical manufacturing locations. Allied to this important development, Sabien has signed an agreement with Lockular to provide robust data security. Lockular's platform is agnostic as to which operations are contained on it and, as a result, this agreement provides scalability, Big Data collection and AI insights for further acquisitions which the Company may make, potentially decreasing the time required to generate value. In combination, these actions have given the Company confidence to commit to the next generation of M2G, integrating remote commercial boiler management within a single Cloud-enabled device.

Consistent with these developments throughout the year, and the Company's wider strategy, Sabien has strengthened its management team with the appointments of Danny Mills as President of the U.S. subsidiary,Sabien Inc., Dr. Athan Fox as Chief Scientific Officer and Tom Sprunt as Managing Director (non-Board). Mr. Mills is a US-based investor and technology operator who has worked with Sabien's leadership for a number of years. In combination with Richard Parris' work in US markets, Mr. Mills provides the necessary experience to benefit from President Biden's Plan for a Clean Energy Revolution and Environmental Justice. Dr. Fox's experience encompasses organic chemistry, intellectual property prosecution, technology transfer and fund raising for research, technology and innovation. Through Dr. Fox's work, Sabien is confident of a value-creating entry to the waste-to-energy market. Mr. Sprunt has many years' commercial experience in the boiler management industry.

In all cases, the new appointments bring a wealth of relevant experience and understanding of key markets for the Company.

Sabien's final results are expected to be published by the end of August 2021. The Board expects that these results will demonstrate the financial strength of the Company following the placing in February 2021. In addition, the Group has generated revenue of £0.97m in the year (2020: £0.45m), with £0.56m recorded in the second half, an increase of 89% on the £0.30m for the same period in the previous year. Sabien also carries circa £43k of open orders into FY22.

As at 30 June 2021, Sabien had cash in hand of £1.40m (2020: £0.78m).

Commenting on the 2021 financial year, Richard Parris, Chairman of Sabien, stated:

"The Board of Sabien faces an array of opportunities within its chosen market areas. In market capitalisation terms, Sabien is a small company listed on AIM. Executing an expansion strategy via acquisition can be challenging and expensive due to necessary market regulation. The Board will not be deterred by these challenges, and we are actively considering innovative structures within which to maximise the returns to shareholders as soon as possible while minimising execution expenses.

During the year under review, the Company has achieved already a number of key goals. From developing our core service, through strengthening the management team, to improving the Company's financial strength, the year to June 2021 has been one of progress. The Board looks forward to the coming year with considerable confidence. In addition to the number of exciting opportunities, several of which could come to fruition in the short to medium term, we are building a corporate structure which will ensure that this expansion delivers value to shareholders and maintains Sabien's ability to develop further. I look forward to reporting to shareholders in more detail in August."

 

For Further Information:

Sabien Technology Group plc

Richard Parris, Executive Chairman 

 

 +44 20 7993 3700 

Allenby Capital Limited (Nominated Adviser)

John Depasquale / Nick Harris 

 

 

+44 203 328 5656

 

Peterhouse Capital Limited (Broker)

Duncan Vasey / Lucy Williams 

 

+44 207 469 0930

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUNUBRAOUBRAR
Date   Source Headline
11th Jun 20267:00 amRNSIssue of shares to directors & broker
2nd Jun 20267:00 amRNSProposed balance sheet strengthening & M2G update
29th May 20265:00 pmRNSTotal Voting Rights
21st May 20267:00 amRNSProposed Commercial Partnership & Investment
20th May 20266:22 pmRNSSettlement of Historical Contract
31st Mar 20267:00 amRNSHalf-year Report for the 6 months to 31 Dec 2025
10th Feb 20267:00 amRNSDirector/PDMR Shareholding
16th Jan 20265:30 pmRNSHolding(s) in Company
22nd Dec 202512:02 pmRNSUpdate on Funding and Strategic Arrangements
22nd Dec 202512:02 pmRNSUpdate on Funding and Strategic Arrangements
9th Dec 20251:20 pmRNSResult of Annual General Meeting
9th Dec 20257:00 amRNSAGM Statement & Trading Update
19th Nov 20257:00 amRNSProposed Strategic Agreement with COF
13th Nov 20257:00 amRNSFinal Results for the Year Ended 30 June 2025
10th Nov 20257:00 amRNSNew Factoring Facility
5th Nov 202512:01 pmRNSAppointment of Corporate Broker
2nd Oct 202512:06 pmRNSFurther update on Sabien, b.grn & related matters
19th Sep 20257:00 amRNSTrading Update
31st Jul 20254:59 pmRNSTotal Voting Rights
8th Jul 20257:00 amRNSYear End Trading Update
30th Jun 20252:53 pmRNSIssue of shares to directors
23rd Jun 20254:28 pmRNSHolding(s) in Company
17th Mar 20257:00 amRNSHalf-year Report for the 6 months to 31 Dec 2024
6th Feb 202511:43 amRNSUpdate in relation to Aeristech Limited
27th Jan 20257:00 amRNSTrading update - acceleration of new M2G orders
31st Dec 202412:30 pmRNSTotal Voting Rights
19th Dec 202410:51 amRNSResult of Annual General Meeting
19th Dec 20247:00 amRNSUpdate on US Waste Plastics to Oil Project
28th Nov 20247:00 amRNSDirector/PDMR Shareholding
19th Nov 20247:00 amRNSIssue of shares to non-executive directors
18th Nov 20247:00 amRNSFinal Results & Annual Report & Accounts for 2024
11th Nov 20247:00 amRNSNew M2G Cloud Connection System Order
17th Oct 20247:00 amRNSUpdate on US Waste Plastics to Oil Project
30th Sep 20245:00 pmRNSTotal Voting Rights
26th Sep 20244:21 pmRNSDirector/PDMR Shareholding
19th Sep 20241:00 pmRNSHolding(s) in Company
4th Sep 20245:30 pmRNSAdmission of New Shares & Total Voting Rights
29th Aug 20244:00 pmRNSUpdate on Admission of New Ordinary Shares
20th Aug 20247:00 amRNSRelated Party Funding
8th Jul 20248:15 amRNSTrading Statement
28th Mar 20242:30 pmRNSDirector/PDMR Shareholding
8th Mar 20247:00 amRNSHolding(s) in Company
6th Mar 20247:00 amRNSHolding(s) in Company
5th Mar 202411:52 amRNSHolding(s) in Company
29th Feb 20245:00 pmRNSTotal Voting Rights
21st Feb 202411:27 amRNSResult of Broker Option, Issue of Equity and TVR
20th Feb 20243:45 pmRNSDirector/PDMR Shareholding
19th Feb 20247:45 amRNSPlacement and Broker Option
19th Feb 20247:30 amRNSHalf-year Report for the 6 months to 31 Dec 2023
7th Feb 20247:00 amRNSNew system installed at Hampton Court Palace

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.